Pro Medicus (ASX:PME) Wins Virtua Health Cloud Imaging Contract Worth A$43M Over Seven Years

Sonal Goyal

21 October 2026 01:23 PM AEDT

Pro Medicus (ASX:PME) Wins Virtua Health Cloud Imaging Contract Worth A$43M Over Seven Years

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Pro Medicus subsidiary Visage Imaging has signed a seven-year contract worth A$43 million with Virtua Health, an academic health system in South Jersey.
The contract covers Visage 7 Viewer, Workflow, Open Archive and Cardiology, delivered as a single cloud-based enterprise imaging platform.
The contract uses a transaction-based licensing model, which the company describes as carrying potential upside.
Planning for the rollout begins immediately, with go-live targeted for late in the second quarter or early in the third quarter of calendar 2027.

Pro Medicus Limited (ASX:PME) has signed a seven-year, A$43 million contract with Virtua Health, an academic health system based in South Jersey, in the U.S. state of New Jersey. The agreement was signed by the company's wholly-owned U.S. subsidiary, Visage Imaging, Inc., and covers a cloud-based enterprise imaging platform built on the Visage 7 suite of products. Pro Medicus said the contract is based on a transactional licensing model and that planning for the rollout is to commence immediately.

Contract Terms and the Parties Involved

Spread evenly over its seven-year term, the A$43 million works out at about A$6.1 million a year, although the company did not give a year-by-year breakdown. It described the arrangement as a transactional licensing model, and its summary of the deal says the model carries potential upside. The contract was signed by Visage Imaging, Inc.; Pro Medicus acquired Visage Imaging in January 2009, almost 18 years before this contract. Pro Medicus did not state the contract's start date or its payment schedule.

Pro Medicus described Virtua as an academic health system committed to helping the people of South Jersey be well, get well and stay well. Virtua has 15,000 colleagues and 3,000 affiliated doctors and clinicians, providing care across five hospitals, and it is academically affiliated with Rowan University, Penn Medicine and the Children's Hospital of Philadelphia.

Pro Medicus was founded in 1983 and provides medical imaging software and services to hospitals, imaging centres and health care groups worldwide. It has offices in Melbourne, Berlin and San Diego, and its products include artificial intelligence and e-health solutions alongside the Visage imaging suite. The company describes itself as a healthcare informatics company and says the Visage 7 suite can be deployed in both public and private cloud environments.

Four Visage 7 Modules Across One Unified Platform

The contract covers four components: Visage 7 Viewer, Visage 7 Workflow, Visage 7 Open Archive and Visage 7 Cardiology Imaging. Together they form what the company calls a single, unified enterprise imaging platform, implemented throughout Virtua and delivered in the cloud. Visage will complete the migration from Virtua's legacy PACS archives, its existing image storage systems, to Visage 7 Open Archive. The migration means the images held in the older archives are to be moved into the new platform.

Visage 7 will also provide enterprise distribution of images that is integrated with Virtua's electronic health record (EHR). The rollout will follow Visage's cloud-based implementation process, which the company has described as proven. The contract spans all three core Visage products that the company groups as its full stack, namely viewer, workflow and archive, with cardiology imaging as an additional module rather than a separate system.

Rollout Timeline and Comments From the Chief Executive

Planning for the rollout is to commence immediately. Go-live is the point at which the platform starts operating for Virtua's users. It is targeted for late in the second quarter or early in the third quarter of the 2027 calendar year, which puts it around June to July 2027, roughly eight to nine months after the contract was disclosed on 21 October 2026.

Chief Executive Dr Sam Hupert said Virtua joins a growing list of Visage 7 clients that have chosen the company's fully cloud-based platform, which he said is becoming the standard in the North American healthcare IT market as a result of the CloudPACS strategy. He added that Virtua's choice of the cardiology offering gives it a unified enterprise imaging solution, a trend he said he sees continuing as more healthcare enterprises look to consolidate separate imaging systems.

Hupert also said the sales pipeline spans all market segments, and that interest is growing in the full stack solution made up of the three core Visage products, namely viewer, workflow and archive, with the added option of other specialties such as cardiology.

Where the Virtua Contract Stands

Pro Medicus Limited (ASX:PME) has a seven-year, A$43 million contract in place with Virtua Health for the Visage 7 Enterprise Imaging Platform, signed by Visage Imaging, Inc. and priced on a transactional licensing model. The scope covers Viewer, Workflow, Open Archive and Cardiology Imaging, the migration of Virtua's legacy PACS archives and image distribution integrated with its electronic health record. Planning starts immediately and go-live is targeted for late in the second quarter or early in the third quarter of calendar 2027.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.